Phase 1 Study Of SNX-5422 Mesylate In Adults With Refractory Solid Tumor Malignancies And Lymphomas
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Solid Tumor Malignancy, Lymphoid Malignancy (Lymphoma and CLL), Leukemia, Lymphoma
Both
Solid Tumor Malignancy, Lymphoid Malignancy (Lymphoma and CLL), Leukemia, Lymphoma
Trial Information
Phase 1 Study Of SNX-5422 Mesylate In Adults With Refractory Solid Tumor Malignancies And Lymphomas
Inclusion Criteria:
- Solid tumors or lymphoid malignancies refractory to standard therapy
- measurable disease
- recovery to Grade < 1 toxicity due to prior adverse event or chemotherapy
- no chemotherapy within 4 weeks of entering study
- Age > 18 years
- Karnofsy >= 60%
- Life expectancy > 3 months
- normal or adequate organ and marrow function
Exclusion Criteria:
- receiving other investigational agents
- brain metastases
- uncontrolled medical illness
- HIV+ receiving combination antiretroviral therapy
- significant GI disease
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
MTD, safety and toxicity
Outcome Time Frame:
continuous
Safety Issue:
Yes
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
United States: Food and Drug Administration
Study ID:
B1311003
NCT ID:
NCT00647764
Start Date:
March 2008
Completion Date:
September 2010
Related Keywords:
- Solid Tumor Malignancy
- Lymphoid Malignancy (Lymphoma and CLL)
- Leukemia
- Lymphoma
- Neoplasms
- Leukemia
- Lymphoma
Name | Location |
|---|---|
| Pfizer Investigational Site | Westminster, Maryland 21157 |
